Evidence map›Paper›PMID 39129279›Full record

ArticleCurrent pharmaceutical design2024

Weight,

Ke Hu, Jia-Jun Pan, Wen-Qian Qu, Su-Mei He, Yang Yang, Hao-Zhe Shi, Yi-Jia Zhang, Xiao Chen, Dong-Dong Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ke HuJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.
Jia-Jun PanDepartment of Thoracic Cardiovascular Surgery, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221100, China.
Wen-Qian QuDepartment of General Surgery, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200040, China.
Su-Mei HeDepartment of Pharmacy, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, Jiangsu 215153, China.
Yang YangDepartment of Pharmacy, The Affiliated Changzhou Children's Hospital of Nantong University, Changzhou, Jiangsu 213003, Chin.
Hao-Zhe ShiJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.
Yi-Jia ZhangJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.
Xiao ChenSchool of Nursing, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.
Dong-Dong WangJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.

Funding

Changzhou Science and Technology Bureau CJ20229030Jiangsu Provincial Commission of Health and Family Planning No. Z2023010Jiangsu Provincial Department of Education (2023JSETKT136,C/2022/01/36Xuzhou Medical University No. RC20552111,(No. X1d202209,(No. Xjyzrd202304,No. XYRHCX2022005),(No. XYRHCX2021011,No. RC2055222
6 · The paper itself

Abstract

objectiveThe method of administering the initial doses of tacrolimus in recipients of pediatric lung transplantation, especially in patients with low hematocrit, is not clear. The present study aims to explore whether weight,

methodsThe present study utilized the tacrolimus population pharmacokinetic model, which was employed in lung transplantation recipients with low hematocrit.

resultsFor pediatric lung transplantation recipients not carrying

conclusionThe present study is the first to recommend the initial dosages of tacrolimus in recipients of pediatric lung transplantation with low hematocrit using a simulation model.

Indexed as

Cytochrome P-450 CYP3AGenotypeImmunosuppressive AgentsLung TransplantationTacrolimusVoriconazoleAdolescentAntifungal AgentsBody WeightChildComputer SimulationDose-Response Relationship, DrugHematocritHumansAntifungal AgentsCYP3A5 protein, humanCytochrome P-450 CYP3AImmunosuppressive AgentsTacrolimusVoriconazoleCYP3A5 genotypeInitial dosagelow hematocritpediatric lung transplantationtacrolimusvoriconazole.

Identifiers

PMID39129279

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.